In this segment, Dr. Greg Randolph outlines the foundational principles of managing advanced differentiated thyroid cancer (DTC), emphasizing the central role of surgery. He explains that for most solid tumors, including DTC, surgery remains the optimal initial therapy when it can be performed safely and completely. Surgery is typically followed by radioactive iodine, forming the mainstay of first-line treatment.
In this segment, Dr. Greg Randolph explains how clinicians evaluate patients with advanced differentiated thyroid cancer (DTC) to guide initial treatment decisions. He emphasizes that the most critical issue is determining the extent of locoregional invasion, specifically tumor location, visceral involvement (trachea, larynx, esophagus, great vessels), and neural involvement.
In this segment, Dr. Greg Randolph discusses how the treatment landscape evolves when differentiated thyroid cancer (DTC) progresses beyond traditional local therapies such as surgery and radioactive iodine.
In this segment, Dr. Greg Randolph explores when and how systemic therapy is introduced for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
In this segment, Dr. Greg Randolph walks through a case of a 66-year-old patient with differentiated thyroid cancer (DTC) who initially does well after thyroidectomy and radioactive iodine, but later develops cervical nodal recurrence and small pulmonary metastases.
In this segment, Dr. Greg Randolph discusses how and when systemic therapy is selected for patients with progressive differentiated thyroid cancer (DTC), emphasizing that these are nuanced, team-based decisions rather than simple algorithmic steps.
In this closing segment, Dr. Greg Randolph distills key lessons for clinicians managing patients with differentiated thyroid cancer (DTC), particularly those whose disease progresses over time.
